J.P. Morgan recently met with Hospira's HSP management team “and wanted to share our quick takeaways and highlights from the discussion.”
“Specifically, we remain upbeat about generic Taxotere dynamics and comfortable with our above guidance forecast of $4.05 for 2011 EPS,” J.P. Morgan writes. “Beyond Taxotere, we see several of the overhangs that impacted the company's results in 2010 (manufacturing warning letters, Plum and Symbiq challenges) lifting as we move through the next 9-12 months, and we are maintaining our Overweight rating.”
Hospira closed Wednesday at $54.89.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in